Eladur, an investigational transdermal drug patch for low back pain, did not meet goals in a double-blind study, according to a report by its maker, Durect.
Eladur delivers for up to three days bupivacaine, an FDA-approved long-acting local anesthetic used in regional anesthesia for local tissue infiltration, nerve block, and epidural and intrathecal anesthesia.
“Demonstrating efficacy against placebo in a chronic low back pain trial is challenging for any topical locally acting product,” said James E. Brown, president and CEO of Durect. “We and Pfizer are continuing to analyze this most recent study and will work together to determine next steps.”
Read the Durect report on Eladur.
Read more coverage of low back pain.
– Imaging Doesn’t Benefit Most Low Back Pain
– Study Finds Many Back Pain Patients Overtreated
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
